Drug library screen to identify compounds that decrease secreted Abeta from a human cell line.
In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid beta peptide (Abeta) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Abeta accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 microM. Three of these seven compounds were more effective than the others at reducing Abeta levels in a tertiary screen, and led to 68 to 85% reductions in total Abeta, at the 25 microM dosage. The effects of these three drugs on secreted Abeta40, Abeta42, and sAPPalpha were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.
Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA.
Enakshi
E
Chakrabarti
Jonathan D
JD
Smith
D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology
D016229:Amyloid beta-Peptides; D018696:Neuroprotective Agents